Tengion, Inc. - 500 Beiträge pro Seite

[benefactor [KommA]]

Business Summary:
Tengion, Inc., a regenerative medicine company, focuses on discovering, developing, manufacturing, and commercializing a range of replacement organs and tissues, or neo-organs and neo-tissues to address unmet medical needs in urologic, renal, gastrointestinal and vascular diseases. It creates these functional neo-organs and neo-tissues using a patient’s own cells, or autologous cells, in conjunction with the company’s Organ Regeneration Platform. The company’s lead product candidate, the Neo-Urinary Conduit, is an autologous implant that catalyzes regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal, or cystectomy. Its product pipeline also includes various candidates in early stage development, such as Neo-Kidney Augment for patients with advanced chronic kidney disease, or CKD. The company was founded in 2003 and is headquartered in East Norriton, Pennsylvania.
http://www.tengion.com/

Im März gab es Insiderkäufe von 2,473,500 Aktien bei einem Kurs von $2,83. Aktuell steht der Kurs bei $0,86. Geld hat Tengion noch genug um weiterzumachen. Ich glaube hier sind durchaus Kurse von 100% plus möglich, jedoch könnte ich mir vorstellen das es kurzfristig noch weiter runter geht.

[benefactor [KommA]]

Antwort auf Beitrag Nr.: 42.028.290 von benefactor am 31.08.11 20:34:54

Hier noch die passende Meldung warum der Kurs im Mai abgestürzt ist.

Market Pulse Archives

May 13, 2011, 10:43 a.m. EDT
Tengion plunges 20% on clinical trial setback

By Val Brickates Kennedy

BOSTON (MarketWatch) -- Shares of Tengion Inc. TNGN plunged 20% in early trading Friday after it announced a delay in a key clinical trial for its bladder cancer product Neo-Urinary Conduit, or NUC. Tengion said that due to various patient complications, interim results from the trial will not be available until 2012. On Thursday, Tengion reported a narrowed adjusted quarterly loss of 41 cents a share versus $1.04 a share. Analysts at Leerink Swann lowered their rating of the stock to market perform from outperform on Friday, citing concerns about the NUC program and the company's cash position.

[benefactor [KommA]]

Tengion Resumes Patient Enrollment in Clinical Trial of Neo-Urinary Conduit Program

prnewswire

Press Release Source: Tengion, Inc. On Tuesday September 13, 2011, 8:30 am EDT

EAST NORRITON, Pa., Sept. 13, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq:TNGN - News) today announced that it has reinitiated enrollment of patients in the ongoing initial clinical trial of its lead product candidate, the Neo-Urinary Conduit™, which is being evaluated in bladder cancer patients requiring a urinary diversion following bladder removal (cystectomy).

"We are pleased to resume screening procedures to enroll the next patient in our ongoing trial," said Sunita Sheth, M.D., Chief Medical Officer and Vice President Clinical and Regulatory Affairs of Tengion. "We anticipate enrolling our fourth patient during the fourth quarter of this year, followed by another patient during the first quarter of 2012. After enrolling the fifth patient and safety data permitting, we intend to discuss with clinical investigators and the Data Safety Monitoring Board a reduction in the amount of time between future patient implants."

Brian Davis, Chief Financial Officer and Vice President, Finance of Tengion, will present this update at the Rodman & Renshaw 13th Annual Healthcare Conference later today at 1:35 pm EDT. Mr. Davis' presentation can be viewed at http://www.wsw.com/webcast/rrshq20/tngn and a live webcast of his presentation can be accessed later today under "Calendar of Events" in the Investors section of the Company's website at www.tengion.com.

This ongoing trial is designed to assess the safety and preliminary efficacy of the Neo-Urinary Conduit, as well as to allow the clinical investigators to optimize the surgical procedure and post-surgical care by incorporating the outcomes observed in each patient into the surgical approach for subsequent patients, as necessary. The trial is being conducted at the University of Chicago Medical Center and at The Johns Hopkins Hospital in Baltimore, Maryland. To date, three patients have been enrolled and implanted in the clinical trial. Data from these patients have allowed clinical investigators to make surgical modifications for the trial moving forward in an effort to address conduit patency and vascular supply. Tengion recently submitted these surgical modifications and additional clinical data from the trial to the U.S. Food and Drug Administration (FDA), enabling the resumption of enrollment of additional patients.

About the Neo-Urinary Conduit

The Neo-Urinary Conduit is a combination of a patient's own cells and bioabsorbable scaffold that is intended to catalyze regeneration of a native bladder tissue conduit, passively transporting urine from the ureters through a stoma, or hole in the abdomen, into a standard ostomy bag. Patients requiring some form of urinary diversion with today's standard of care, the use of a segment of bowel tissue to construct a conduit for urine to exit from the body into an ostomy bag, are at risk of complications associated with the use of bowel tissue as well as those associated with the surgery to harvest the bowel tissue.

About Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company's lead preclinical candidate is the Neo-Kidney Augment, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure. Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment for the treatment of neurogenic bladder. Tengion has worldwide rights to its product candidates.